Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 3/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.45 |
| ▸ | PDE4A | P27815 | 2/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.45 |
| ▸ | GLP1R | P43220 | 12/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30568152 | 1.00 | PDE4D (0.45) | PDE4DPDE4BPDE4APDE4CGLP1R | |
| SCHEMBL24330478 | 0.92 | GLP1R (0.45) | GLP1RPRMT5GPR119 | |
| SCHEMBL24329283 | 0.92 | GLP1R (0.46) | PDE4DPDE4BPDE4APDE4CGLP1R | |
| SCHEMBL24329574 | 0.90 | PRMT5 (0.42) | PDE4DPDE4BPDE4APDE4CGLP1R | |
| SCHEMBL29555882 | 0.89 | GLP1R (0.52) | GLP1RPRMT5GPR119 | |
| SCHEMBL24329531 | 0.89 | GLP1R (0.52) | GLP1RPRMT5GPR119 | |
| SCHEMBL24329515 | 0.89 | GLP1R (0.49) | GLP1RPRMT5GPR119 | |
| SCHEMBL29555009 | 0.89 | GLP1R (0.48) | GLP1R | |
| SCHEMBL24329496 | 0.88 | GLP1R (0.55) | GLP1RGPR119 | |
| SCHEMBL24329782 | 0.88 | GLP1R (0.45) | GLP1RGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263402-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2025-08-21 | — | — | US | disclosed |
| EP-4227299-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) | 2023-08-16 | — | — | EP | disclosed |
| EP-4227299-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) | 2023-08-16 | — | — | EP | disclosed |
| CN-116348464-A | Benzimidazolone GLP-1 receptor agonists and uses thereof | 杭州中美华东制药有限公司 | 2023-06-27 | — | — | CN | disclosed |
| WO-2022078152-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | 杭州中美华东制药有限公司 | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263402-A1 | BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF | GLP1R, GIPR, GCGR | PDE4D 484/4885PDE4B 587/4885PDE4A 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.